The United Kingdom's healthcare regulator on Friday said it had made the world's largest seizure of illegal weight loss ...

In a recent regulatory update, the Central Drugs Standard Control Organisation (CDSCO) has formally approved the withdrawal ...

Against the backdrop of global trade policy uncertainties, even the threat of high tariffs may not be able to stop the upward momentum of certain high-quality stocks. Taking pharmaceutical giant ...

Britain's medicines regulator said on Friday it had made the world's largest seizure of unlicensed weight-loss medicines, ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a caller’s ...

Analysts believe that while the deal is positive, Cipla's share price is unlikely to see a fresh run-up, given the rise it ...

Lilly and Inctye will be seeking a label update for the JAK inhibitor for its use in paediatric patients with alopecia areata ...

Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...

Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a ...